Is BimAb a funded company?

BimAb is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does BimAb rank among its competitors?

BimAb ranks 94th amongst 90 active competitors, of which 16 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Slingshot Bioscience, which secured $11M in Feb, 2023.

Who are the top competitors of BimAb?

BimAb's top competitors include HitGen, Slingshot Bioscience and InterAx Biotech. Among them, Slingshot Bioscience secured the most recent funding round in February, 2023.

BimAb - 2026 Company Profile & Competitors

BimAb is an unfunded company. It operates as a Developer of monoclonal antibodies bispecific antibodies nanobodies and short peptides. BimAb has not raised any funding yet. The company has 90 active competitors, including 16 funded and 8 that have exited. Its top competitors include companies like HitGen, Slingshot Bioscience and InterAx Biotech.

Company Details

Developer of monoclonal antibodies bispecific antibodies nanobodies and short peptides. This entity provides discovery and engineering services for biological reagents used in research diagnostics and therapeutics. The business utilizes an in vitro platform to screen and isolate molecules based on affinity specificity stability and expression requirements. Services include the development of customized biologics to meet specific technical specifications for research and therapeutic applications.

Key Metrics

Stage

Unfunded

Ranked

94^th among 94 competitors

Similar Companies

HitGen & 92 more

View BimAb's full profile

BimAb has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BimAb include HitGen, Slingshot Bioscience and InterAx Biotech. Here is the list of Top 10 competitors of BimAb, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HitGen 2012, Lanzhou (China), Public	Developer of DNA encoded libraries for drug discovery	$39.1M	CDH, Shiyu & 2 others	57/100
2nd	Slingshot Bioscience 2012, Berkeley (United States), Series A	Developer of next-generation synthetic cells for diagnostics and therapeutics	$46.4M	Northpond Ventures, Arch Venture Partners ... & 2 others	56/100
3rd	InterAx Biotech 2016, Villigen (Switzerland), Series A	Arrestin-based biosensors and computational methods for GPCR based drug discovery	$3.19M	Verve Ventures, Venture Kick & 5 others	53/100
4th	Passkey Therapeutics 2022, Cambridge (United States), Unfunded	Developer of multifunctional therapeutics targeting rare combinations of proteins	-	-	48/100
5th	Sequence Bio 2013, St John s (Canada), Seed	Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.	$5.47M	DCVC, Killick Capital & 5 others	45/100
6th	Vectus Biosystems 2005, Rosebery (Australia), Public	Develops drug discovery platform	-	-	44/100
7th	StemoniX 2014, San Diego (United States), Acquired	Engineering human brain and nerve models for neurological insights	$33.7M	EvoNexus, Gopher Angels & 19 others	44/100
8th	Aucta Pharmaceuticals 2012, New Brunswick (United States), Seed	Innovating enhanced therapeutics using technology for specialty brand and generic products	-	Shanghai Changjiang Guohong Investment Management, SDIC Venture Capital Management ... & 3 others	42/100
9th	Signal Pharmaceuticals 1993, San Diego (United States), Acquired	Discoverer of drugs to regulate disease-related genes	$12M	Venrock, The Vertical Group & 10 others	40/100
10th	ZoBio 2004, Leiden (Netherlands), Acquired	Provider of fragment-based drug discovery services	-	Europa, Libertatis Ergo Holding	40/100
94th	BimAb Unfunded	Developer of monoclonal antibodies bispecific antibodies nanobodies and short peptides	-	-	-